HomeSAVA • NASDAQ
add
Cassava Sciences Inc
Previous close
$2.05
Day range
$2.01 - $2.32
Year range
$1.15 - $42.20
Market cap
100.96M USD
Avg Volume
973.24K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 7.92M | 18.19% |
Net income | -23.40M | -193.45% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -21.37M | 5.56% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 117.33M | -5.51% |
Total assets | 140.93M | -9.50% |
Total liabilities | 13.32M | -82.73% |
Total equity | 127.62M | — |
Shares outstanding | 48.31M | — |
Price to book | 0.78 | — |
Return on assets | -36.16% | — |
Return on capital | -39.49% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -23.40M | -193.45% |
Cash from operations | -11.34M | 40.73% |
Cash from investing | — | — |
Cash from financing | 90.00K | -99.59% |
Net change in cash | -11.25M | -470.79% |
Free cash flow | -1.42M | -102.85% |
About
Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Sciences, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was a Cassava senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Cassava, Barbier, Burns and Wang. The parties did not admit wrongdoing, but a settlement of the SEC charges, pending court approval, would fine Cassava $US40 million, Barbier $175 thousand, Burns $85 thousand and Wang $50 thousand.
Cassava was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019. Wikipedia
Founded
1998
Headquarters
Website
Employees
30
